First generic companies move towards advanced overseas market for better conditions

Published: 2003-07-07 06:58:00

Updated: 2003-07-07 06:58:00

The advancement of domestic export-oriented, first-generic pharmaceutical companies into advanced countries such as U.S. and Europe is gaining momentum via a series of export stimulus measures, in a bid to overcome more intensified assaults by India and China in the Asian and South American marke...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK